nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Adalimumab Plus Methotrexate versus Methotrexate Monotherapy in Early RA
|
Rizzo, Toni |
|
2012 |
12 |
9 |
p. 16-16 |
artikel |
2 |
Anti-TNF Therapy and CV Risk in RA
|
Rizzo, Toni |
|
2012 |
12 |
9 |
p. 12-13 |
artikel |
3 |
Cardiovascular Disease Impact in Rheumatic Disease
|
Rizzo, Toni |
|
2012 |
12 |
9 |
p. 4-5 |
artikel |
4 |
Clinical and Radiological Outcomes of Four DAS ≤2.4 Targeted Treatment Strategies: Eight-Year Results from the BeSt Study
|
Vinall, Maria |
|
2012 |
12 |
9 |
p. 18-19 |
artikel |
5 |
Efficacy and Safety of NNC0109-0012 (Anti-IL-20 mAb) in Patients with RA: Results from a Phase 2a Trial
|
Vinall, Maria |
|
2012 |
12 |
9 |
p. 9-10 |
artikel |
6 |
Efficacy of Different Doses of Rituximab for the Treatment of RA: Data from the CERERRA Collaboration
|
Rizzo, Toni |
|
2012 |
12 |
9 |
p. 11-12 |
artikel |
7 |
EULAR/ERA-EDTA Lupus Nephritis Recommendations
|
Rizzo, Toni |
|
2012 |
12 |
9 |
p. 30-30 |
artikel |
8 |
FREEDOM Trial Analysis: Denosumab Discontinuation and Associated Fracture Incidence
|
Rizzo, Toni |
|
2012 |
12 |
9 |
p. 28-28 |
artikel |
9 |
Guidelines for the Management of Primary Systemic Vasculitis
|
Rizzo, Toni |
|
2012 |
12 |
9 |
p. 29-29 |
artikel |
10 |
Inflammation and Fatty Degeneration in New Bone Formation in Patients with AS Treated with Anti-TNF Agents
|
Rizzo, Toni |
|
2012 |
12 |
9 |
p. 19-20 |
artikel |
11 |
Interview with the EULAR President
|
Vinall, Maria |
|
2012 |
12 |
9 |
p. 6-6 |
artikel |
12 |
LITHE Study Subset: Identification of Tocilizumab Early Response-Associated Biomarkers
|
Buckley, Rita |
|
2012 |
12 |
9 |
p. 15-15 |
artikel |
13 |
Lung Ultrasound for Screening Interstitial Lung Disease
|
Rizzo, Toni |
|
2012 |
12 |
9 |
p. 20-20 |
artikel |
14 |
Naïve to Biologic Therapy or Inadequate Responders to TNF-α Inhibitors: A Phase 2 Study of LY2439821
|
Vinall, Maria |
|
2012 |
12 |
9 |
p. 14-15 |
artikel |
15 |
One-Year Results from the AMPLE Study
|
Vinall, Maria |
|
2012 |
12 |
9 |
p. 7-7 |
artikel |
16 |
Results from the ESPOIR Cohort Study
|
Rizzo, Toni |
|
2012 |
12 |
9 |
p. 16-17 |
artikel |
17 |
Small Molecules for Rheumatoid Arthritis
|
Rizzo, Toni |
|
2012 |
12 |
9 |
p. 26-27 |
artikel |
18 |
The ASTIS Trial: First Results
|
Vinall, Maria |
|
2012 |
12 |
9 |
p. 8-8 |
artikel |
19 |
Towards Imaging Remission: Determining an MRI Inflammatory Activity-Acceptable State in RA
|
Rizzo, Toni |
|
2012 |
12 |
9 |
p. 21-22 |
artikel |
20 |
Update on ACR/EULAR RA Classification Criteria: What Have We Learned?
|
Vinall, Maria |
|
2012 |
12 |
9 |
p. 23-25 |
artikel |
21 |
24-Week Data from the Phase 4 ADACTA Trial
|
Vinall, Maria |
|
2012 |
12 |
9 |
p. 10-11 |
artikel |
22 |
24-Week Results from the RAPID-PsA Study
|
Vinall, Maria |
|
2012 |
12 |
9 |
p. 8-9 |
artikel |
23 |
12-Week Results of a Phase 2b Dose-Ranging Study of Baricitinib (LY3009104) in Combination with Traditional DMARDs in Patients with RA
|
Vinall, Maria |
|
2012 |
12 |
9 |
p. 13-14 |
artikel |
24 |
2-Year Results from the GO-RAISE Trial
|
Rizzo, Toni |
|
2012 |
12 |
9 |
p. 17-18 |
artikel |